SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (1608)10/21/2005 11:57:22 AM
From: tom pope  Read Replies (1) of 1826
 
I don't remember whether I posted this snippet from yesterday's Merrill Morning Call or not:

MGI Pharma (MOGN, $22.82, C-1-9)
Reiterate Buy and $28 PT. Q3 Results: Lowering 05E to $0.36 from $0.53
& 06E to $0.59 from $0.92 due to Higher Spending. 3Q in-line w/ preannounced
guidance. Importantly, collected all required transfusion data
from the phase III Dacogen study - should enable an NDA re-filing by
11/15. Also, the Aquavan phase II dosing study is fully enrolled with data
expected by YE05 and a pivotal trial starting in early ‘06. Guided large
launch expenses for Dacogen, & R&D spending for Aquavan’s phase III
trial along w/ pipeline products (Aloxi for PONV, Dacogen for AML, &
ZYC101a).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News